Nanomedicines: Future Against Infections

摘要

The World Health Organization estimates that around 1.5 billion people are currently infected with latent Mycobacterial tuberculosis (MTB). However, each year, 8 million people develop active disease and 3 million die. Approximately 20% of these cases are multiple drug resistant (MDR-TB), resistant to the main first-line drugs isoniazid and rifampin, and 2% are extensively drug resistant (XDR-TB), resistant to isoniazid, rifampin, fluoroquinolones and at least one of three secondline drugs (amikacin, kanamycin, or capreomycin). Despite, no new classes of anti-TB drugs or drug formulations have been introduced clinically since the 1980’s [1].